基于专家的共识,为处方数字疗法制定政策成熟度模型: eDelphi研究的协议
João Rocha-Gomes1, Bernardo Sousa-Pinto2, Ana Luisa Neves2,3
1Faculty of Medicine, Department of Community Medicine, Health Information and Decision, University of Porto, Porto, Portugal jngomes@med.up.pt.
BMJ open
|February 15, 2026
概括
本研究开发了一个政策成熟度框架,以评估处方数字治疗药物 (PDTx) 的准备程度. 该eDelphi研究旨在指导这些基于软件的健康解决方案的一致采用.
科学领域:
- 数字健康数字健康
- 卫生政策 卫生政策
- 医疗保健创新 医疗保健创新
背景情况:
- 处方数字疗法 (PDTx) 提供了新的治疗解决方案,但面临着分散的政策格局.
- 监管,补偿和整合的变化为利益相关者创造了采用不确定性.
- 需要一个系统的方法来评估国家或地区对PDTx的准备.
研究的目的:
- 开发和验证一个全面的政策成熟度框架来评估PDTx采用准备.
- 引导决策者,开发人员和提供商在PDTx实施的复杂性中进行导航.
- 建立一个以共识为导向的工具,用于基准测试和推动PDTx融入卫生系统.
主要方法:
- 一项e-Delphi研究,涉及多达三轮,涉及来自六个利益相关方组的各种专家.
- 有目的的抽样优先考虑欧洲专家,具有更广泛的国际视角的潜力.
- 使用5分利克特级别对定量数据和开放文本提示对定性见解,共识定义为≥70%的协议.
主要成果:
- 该研究协议概述了PDTx政策成熟度框架的代改进和验证.
- 在框架领域,评分标准和成熟度值方面将达成共识.
- 经过验证的框架将捕捉PDTx政策制定和实施的基本要素.
结论:
- 开发的框架将为评估和推进PDTx采用提供参考.
- 它旨在减少不确定性,并在各司法管辖区促进一致的政策制定.
- 通过出版物和政策简报进行传播将支持数字健康治理.
相关概念视频
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
17
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
17
01:27Pharmacodynamic Models: Overview
19
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
19
01:26Drug Administration and Therapy Phases: Overview
1.5K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.5K
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
18
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
18
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
20
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
20